Combining Contrave (naltrexone/bupropion) with phentermine is not an FDA-approved combination, and no clinical trials have tested the two drugs taken simultaneously in a controlled setting. Both are individually approved for weight management, but they work through different pathways and carry overlapping side-effect profiles that raise real safety concerns when stacked together. Some clinicians have prescribed them together off-label, but doing so means accepting risks that have not been formally studied.
How Each Drug Works on Its Own
Contrave is a fixed-dose combination of two older medications repurposed for weight loss. Naltrexone is an opioid receptor blocker originally used for alcohol and opioid dependence, and bupropion is an antidepressant that acts on dopamine and norepinephrine signaling in the brain. Together, they are thought to reduce appetite and food cravings by modulating reward pathways in the hypothalamus. Clinical trials showed that people taking Contrave lost roughly 5 to 9 percent of their body weight over a year, depending on the trial and whether behavioral counseling was included.
Phentermine is one of the oldest prescription weight-loss drugs still in use. It is a sympathomimetic amine, meaning it mimics the effects of the body’s “fight or flight” chemicals. It primarily boosts norepinephrine release in the central nervous system, which suppresses appetite. The FDA approved phentermine decades ago for short-term use (typically up to 12 weeks), though many physicians prescribe it for longer periods. A study tracking patients on phentermine for up to two years found that their systolic and diastolic blood pressure actually declined from baseline, and heart rate changes were not significant, alongside sustained weight loss through week 104.1PubMed. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity
Why Combining Them Raises Red Flags
The core concern with taking Contrave and phentermine together is that both drugs increase norepinephrine activity. Bupropion, one of the two active ingredients in Contrave, inhibits the reuptake of both norepinephrine and dopamine. Phentermine directly stimulates norepinephrine release. Layering these effects means a person could end up with significantly elevated norepinephrine levels, which can drive up blood pressure, increase heart rate, and heighten the risk of cardiovascular events. Neither drug alone has been shown to cause major cardiovascular harm in most patients, but the combination amplifies a shared mechanism in ways that have not been tested in large trials.
Seizure risk is another serious concern. Bupropion carries a dose-dependent seizure warning on its own label. Adding phentermine, which is itself a central nervous system stimulant, could theoretically lower the seizure threshold further. There are no controlled data quantifying this risk when the two drugs are combined, which is precisely the problem: the absence of safety data is not the same as evidence of safety.
Beyond the cardiovascular and neurological overlap, there is a metabolic wrinkle. Bupropion is a strong inhibitor of a liver enzyme called CYP2D6, which is involved in processing many common medications.2PubMed Central. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation This enzyme inhibition can change the way other drugs are metabolized, potentially raising their blood levels and intensifying side effects. While phentermine is not primarily cleared through CYP2D6, anyone taking additional medications alongside both Contrave and phentermine faces a more complicated pharmacological picture that requires careful review.3PubMed Central. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
What “Off-Label” Means in This Context
When people report taking Contrave and phentermine together, they are almost always doing so through off-label prescribing. This means a doctor has decided, based on their clinical judgment, that the potential benefit of combining these drugs outweighs the unknown risks for that particular patient. Off-label prescribing is legal and common in medicine; it is not the same as experimental or reckless. But it does mean you are stepping outside the boundaries of what the FDA has reviewed for safety and effectiveness.
Some obesity medicine specialists have written about using combination approaches when a single medication plateaus or provides insufficient weight loss. The rationale is straightforward: if one drug working on one pathway produces modest results, adding a second drug working on a different pathway might produce better outcomes. This logic has worked well for the FDA-approved combination of phentermine with topiramate (sold as Qsymia), where the two drugs were formally studied together and the combination was approved based on that evidence. The difference with Contrave plus phentermine is that no such joint study exists.
If your doctor has suggested or agreed to this combination, it is reasonable to ask them what monitoring they plan to do. Blood pressure checks, heart rate tracking, and regular follow-ups become more important when combining two drugs with overlapping stimulant-like effects.
Side Effects You Would Need to Watch For
Each drug already carries its own side-effect profile, and combining them means you could experience issues from both simultaneously. Contrave’s most common side effects include nausea, constipation, headache, and trouble sleeping. Pooled data from clinical trials found that sleep disturbances were significantly more common in people taking naltrexone/bupropion than in those on placebo, with about 13 percent reporting sleep issues compared to roughly 8 percent on placebo.4PubMed Central. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis Anxiety was also somewhat more frequent at around 5 to 6 percent versus 3 to 4 percent on placebo, though depression rates were not meaningfully higher.5PubMed Central. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
Phentermine’s common side effects include dry mouth, insomnia, constipation, and elevated heart rate. Notice the overlap: both drugs can cause insomnia, both can cause constipation, and both have stimulant-related effects. Taking them together may make these shared side effects more likely or more pronounced. The insomnia overlap is worth special attention, because chronic poor sleep itself undermines weight loss efforts and worsens metabolic health.
More serious adverse events to watch for include:
- Elevated blood pressure: Even though phentermine alone did not raise blood pressure in long-term studies, the combination with bupropion’s norepinephrine effects is uncharted territory.
- Rapid or irregular heartbeat: Both drugs can affect heart rate through their stimulant properties.
- Mood changes: Bupropion carries a black box warning about suicidal ideation in younger adults, and adding a stimulant may alter mood unpredictably.
- Seizures: Any combination that further lowers the seizure threshold in someone already taking bupropion warrants caution.
Why the FDA Has Not Approved This Combination
The FDA’s drug-approval process requires a sponsor (usually a pharmaceutical company) to submit clinical trial data proving that a specific drug or combination is both safe and effective for its intended use. No company has conducted the large, randomized, controlled trials that would be needed to demonstrate that Contrave plus phentermine is safe and works better than either drug alone. This is partly an economic issue: Contrave is made by one company and phentermine is a generic drug made by many, so there is little financial incentive for anyone to fund the expensive trials that would be needed.
The absence of an FDA-approved combination does not necessarily mean the combination is dangerous. It means no one has done the work to find out in a rigorous way. That distinction matters, because it puts the burden of judgment on the prescribing physician and on you as the patient to weigh incomplete information.
What About Phentermine-Topiramate Instead?
If you are looking for a more powerful weight-loss medication than either Contrave or phentermine alone, the FDA-approved combination of phentermine and topiramate (Qsymia) is worth discussing with your doctor. This combination was studied in large clinical trials and received FDA approval based on evidence that it produces more weight loss than either component alone. The two drugs work through different mechanisms: phentermine suppresses appetite through norepinephrine, while topiramate, originally an anti-seizure medication, appears to reduce appetite and increase feelings of fullness through pathways that are not fully understood.
Qsymia is not without its own concerns. Topiramate can cause tingling in the hands and feet, cognitive slowing (sometimes called “brain fog”), and carries a risk of birth defects, so it requires pregnancy prevention measures. But the key advantage over an improvised Contrave-plus-phentermine stack is that the safety profile has been formally studied, side effects are documented with real numbers, and your doctor has published data to guide dosing and monitoring decisions.
The Newer GLP-1 Medications
The weight-loss medication landscape has shifted dramatically with the arrival of GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound). These injectable medications produce substantially more weight loss than either Contrave or phentermine, with average reductions in the range of 15 to 22 percent of body weight in clinical trials. They work through a completely different mechanism, mimicking a gut hormone that slows stomach emptying and acts on brain areas that regulate appetite.
For many people who were considering stacking older medications to get better results, a GLP-1 drug may now be the more straightforward path. The main barriers are cost and access: these medications are expensive, and insurance coverage remains inconsistent. If cost or insurance is the reason you are exploring a Contrave-plus-phentermine approach, that is a common and understandable situation. But it is worth having a frank conversation with your doctor about whether the unknown risks of combining two drugs justify the savings compared to pursuing coverage for a GLP-1 medication or exploring patient assistance programs.
Practical Questions If You Are Already Taking Both
If a doctor has already prescribed both medications for you, there are a few things worth keeping in mind. First, do not adjust doses of either drug on your own. The most common pattern in off-label combination use involves keeping phentermine at the lower end of its dose range and titrating Contrave up slowly, but your doctor should be making these decisions based on your specific health profile.
Timing matters as well. Phentermine is typically taken in the morning because of its stimulant effects, and Contrave is taken twice daily (morning and evening in its standard dosing). The morning overlap means both drugs hit your system at roughly the same time, which is when you might feel the most noticeable stimulant-like effects such as jitteriness, increased heart rate, or difficulty concentrating. If these symptoms are bothersome, your doctor might adjust the timing or reduce a dose rather than abandoning the combination entirely.
Regular monitoring is non-negotiable with this combination. Blood pressure should be checked at least monthly for the first few months, more often if you have a history of hypertension. Keep a log of your resting heart rate at home; a consistent increase of more than 10 beats per minute above your pre-medication baseline is worth reporting. And pay attention to your mood and sleep patterns, because the pooled Contrave trial data showed that psychiatric side effects tended to appear early, often during the first few weeks when the dose is being escalated.6PubMed Central. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
Alcohol, Opioids, and Other Interactions
One interaction that gets less attention but matters a great deal involves opioid pain medications. Naltrexone, the other half of Contrave, blocks opioid receptors. If you take an opioid painkiller while on Contrave, the painkiller will not work properly, and in some cases this can precipitate acute withdrawal symptoms in people who have been using opioids regularly. This is true regardless of whether phentermine is also in the picture, but it becomes a more complex situation if you are managing multiple medications simultaneously.
Alcohol is another concern. Bupropion can lower your tolerance for alcohol and may increase the risk of seizures in people who drink heavily. Phentermine’s prescribing information also cautions against alcohol use. If you are taking both drugs, even moderate drinking becomes riskier than it would be on either drug alone.
Because bupropion strongly inhibits CYP2D6, it can increase blood levels of other medications that rely on that enzyme for processing. Common examples include certain antidepressants, beta-blockers, and some antipsychotic medications.7PubMed Central. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model If you are adding phentermine on top of Contrave, make sure your prescriber has a complete list of everything you take, including over-the-counter supplements, so they can check for these enzyme-related interactions.
When People Hit a Plateau on One Drug
The most common reason people ask about combining Contrave and phentermine is that they have been on one drug, lost some weight, and then stalled. Weight-loss plateaus on anti-obesity medications are extremely common and do not necessarily mean the drug has stopped working. Your body adjusts its metabolic rate and hunger signals over time, and the initial rate of loss almost always slows down after the first few months.
Before adding a second medication, it is worth examining whether behavioral factors have shifted. Calorie intake tends to creep upward over time as people adjust to feeling less hungry and become less vigilant about food choices. Physical activity often decreases as well, especially if the initial weight loss reduced the urgency that motivated exercise. Addressing these behavioral drifts can sometimes restart weight loss without the added risks and costs of a second drug.
If the plateau persists despite genuine behavioral effort, switching to a different single medication is generally a safer first step than stacking two drugs together. Moving from Contrave to phentermine-topiramate, or from phentermine to a GLP-1 medication, keeps you within the bounds of studied, approved therapies. The combination route should be a conversation you have only after simpler options have been explored and found insufficient.